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Antimicrobial activityMono- and binuclear Pt(II) and Pd(II) complexes with 2,20-dithiobis(benzothiazole) (DTBTA) ligand are
reported. [Pt(DTBTA)(DMSO)Cl]Cl∙CHCl3 (1) and [Pd2(m-Cl)2(DTBTA)2]Cl2 (2) have been synthesized and
structurally characterized by elemental analysis, IR, 1H and 13C NMR spectroscopy, MS spectrometry
and the content of platinum and palladium was determined using a flame atomic spectrometer. Two dif-
ferent coordination modes of 1 and 2 complexes were found; in both complexes, the coordination of Pt(II)
and Pd(II) ions involves the N(3) atoms of the ligand but the binuclear complex 2, is a cis-chloro-bridged
palladium complex. Evaluation of their in vitro antitumor activity against two human tumor cell lines
human breast cancer (MCF-7) and hepatocellular carcinoma (HepG2); and their antimicrobial activity
against Escherichia coli and Kokuria rhizophila was performed. Only complex 1 showed a dose- and
time-dependent cytotoxic activity against the two tumor cell lines, associated to apoptosis and accumu-
lation of treated cells in G0/G1 phase of cell cycle, while both 1 and 2 exhibited antimicrobial activity
with complex 1much more potent. The study on intracellular uptake in both MCF-7 and HepG2 cell lines
revealed that only platinum of complex 1 is present inside the cells, suggesting a different mode of action
of the two compounds. This was also in agreement with the results obtained for the antitumor and
antibacterial activity.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
The development of new antimicrobial and anticancer thera-
peutic agents is one of the fundamental goals in medicinal chem-
istry. In this field the chemistry of heterocyclic compounds and
of their complexes with Pt(II) and Pd(II) metallic ions is one of
the leading lines of investigations in both inorganic and organic
chemistry. There are vast numbers of pharmacologically active
heterocyclic compounds, many of which are regularly in clinical
use.Five membered heterocyclic compounds containing Nitrogen,
Sulphur and Oxygen have occupied enormous significance in the
field of drug discovery process.1 Among pharmacologically impor-
tant heterocyclic compounds, the Benzothiazole (BTA) and its
derivatives are the most important heterocyclic compounds,
which are common and integral feature of natural products and
pharmaceutical agents and show a variety of pharmacological
properties. BTA analogs offer a high degree of structural diversity
that has proven to be useful for the search of new therapeutic
agents that exert a wide range of biological activities such as anti-
cancer, antimicrobial, anticonvulsant, antiviral, antitubercular,
antimalarial, anthelmintic, analgesic, anti-inflammatory, antidia-
betic and fungicidal activity.2 The BTA is a heterocyclic compound
in which benzene ring is fused to 4,5-positions of thiazole ring, is
completely planar, and is potentially ambidentate with N and S
available to coordination when it is used as ligand in metal ion
complexes. The thiazole core is present in many biologically rele-
vant molecules, which are in therapeutic use, such as Sulfathiazole
(antimicrobial drug), Ritonavir (antiretroviral drug), Abafungin
(antifungal drug), Tiazofurin (antineoplastic agent), Meloxicam
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zoal agent).3 They contain extended p-delocalized systems which
are capable of binding to DNA molecules via p–p interactions. In
this paper, our scope was to design new molecules for improve-
ment of the use of Pt compounds in chemotherapy, reducing tox-
icity, increasing clinical effectiveness, broader spectrum of action,
elimination of side effects and increasing solubility. Using ben-
zothiazole scaffold and synthetic procedure followed by suitable
modification to generate diversified compounds, new complexes
for antimicrobial and anticancer activity were designed.4 Plat-
inum(II) and palladium(II) ions have similar chemical properties
and modes of coordination forming square planer complexes5; in
fact, they both adopt dsp3 orbital hybridization6, but the palla-
dium compounds are more labile from both a thermodynamic
and a kinetic point of view with respect to corresponding platinum
compounds. Palladium-based drugs can undergo a rapid hydroly-
sis before they reach the DNA target; this results in both a low
antitumor activity or even inactivity and toxicity.7 The use of bulk-
ier chelating ligands can make them active against tumor.8 For this
reason we have chosen to synthesize and characterize with ele-
mental analysis, IR and 1H and 13C NMR spectroscopy, MS spec-
trometry, new mononuclear platinum(II) [Pt(DTBTA)(DMSO)Cl]
Cl∙CHCl3 (1) and binuclear bridged palladium(II) [Pd2(m-Cl)2
(DTBTA)2]Cl2 (2) complexes with a derivate of benzothiazole,
2,20-dithiobis(benzothiazole) (DTBTA) ligand and to study their
biological activity. Our research group has experience in the syn-
thesis and biological study of mono- and polynuclear Pt(II) com-
plexes9–11, so we decided to investigate the antitumor activity of
1 and 2 in vitro against two human cell lines HepG2 and MCF-7.
The antimicrobial activity against Escherichia coli and Kokuria
rhizophila of these compounds is also reported.2. Materials and methods
2.1. General experimental conditions
Dipotassium tetrachloroplatinum(II), dipotassium tetra-
chloropalladium(II), dimethyl sulfoxide and 2,20-dithiobis(ben-
zothiazole) (DTBTA) were purchased from Aldrich (Milan, Italy).
The products were used without further purification. Syntheses
were performed with exclusion of moisture and direct light.
Owing to poor aqueous solubility, the tested complexes, for bio-
logical studies, were dissolved in DMSO and then diluted in culture
medium so that the effective DMSO concentration did not exceed
0.1%. Cell lines of MCF-7 (human breast cancer) and HepG2
(human hepatocellular carcinoma) were purchased from American
Type Culture Collection, Rockville, MD, USA. Elemental analysis for
C, H, N, S, were performed at the Laboratory of Microanalysis
(University of Padova, Italy), chlorine was determined by potentio-
metric titration with standard silver nitrate after combustion in
pure oxygen according to Schöninger.12 The IR spectra were
recorded, as Nujol mulls, with a FT-IR Bruker Vertex 70 Advanced
Research. Conductivity measurements for 103 M solutions in
DMSO were obtained with a Crison GLP 31 Model Conductometer.
The determination of platinum and palladium contents was
obtained using a flame atomic spectrometer Perkin-Elmer 372
and the average of four independent measurements was deter-
mined. 1H and 13C NMR spectra were measured in DMSO-d6 at
300.13 and 75.47 MHz respectively, using a Bruker AC series
300 MHz spectrometer (TMS as an internal standard): chemical
shifts are expressed in d values (ppm). Mass Spectrometry (MS)
spectra were determined with Q-Exactive High Resolution mass
spectrometer (Thermo Scientific, Germany) equipped with the
HESI electrospray source. The experiments were performed in pos-
itive ion mode at a resolving power of 17,500 FWHM (at m/z 200).Samples prepared in 50/50 aqueous/MeOH (20 mL) were intro-
duced into the mass spectrometer by flow infusion using a head
pressure of 35–45 psi at approximately 50 mL/min via the ESI-chip.
To evaluate the cellular uptake, the complexes 1 and 2 were cal-
cined at 600 C in a muffle and the residues were dissolved in solu-
tion of HNO3/HCl (1:3). They were analyzed with Differential Pulse
Voltammetry Amel 433 to calculate the ng/cell of intracellular
metals.
2.2. Chemistry
A general procedure for the synthesis of the complexes 1 and 2
was adopted. The complex 1 was synthesized by Cis-[Pt(DMSO)2-
Cl2]13 (0.33 g, 1 mmol) that was added solid to the chloroform
solution (25 ml) of the DTBTA (0.421 g, 1 mmol); for the complex
2 an aqueous solution of K2PdCl4 (0.26 g, 1 mmol) was added drop-
wise in stirring to the ligand solution (0.27 g, 1 mmol) in ethanol
(30 ml). The resulting solutions were stirred for 24 h at 40 C for
complex 1 and 70 C for complex 2. The orange solids were filtered,
washed with chloroform and dried in vacuum over P4O10.
2.2.1. [Pt(DTBTA)(DMSO)Cl]ClCHCl3 (1)
The complex 1 was prepared following the general procedure.
Yield 40%. Anal. Calc. for (C16H14N2OS5PtCl2)CHCl3 (795.99): C,
25.65; H, 1.90; N, 3.52; S, 20.14; Cl, 22.27; Pt, 24.51%. Found: C,
25.83; H, 1.61; N, 3.63; S, 20.54; Cl, 22.67; Pt, 24.12. Melting point:
>350 C. Conductivity measurements of the complex for 103 M
solution in DMSO afforded a value KM = 31.02X1 cm2 mol1 14
IR (cm1) for the ligand: 1559 v(C@N), 1156 v(C–N), 1006 v(C–S)
and for the complex 1541 v(C@N), 1157 v(C–N), 1006 v(C–S),
1132 v(S@O of coord. DMSO), 349 v(Pt–Cl), 379 v(Pt–S) and 285
v(Pt–N). 1H NMR for the ligand (DMSO-d6, 300 MHz) d ppm: 8.07
(d, 2H, C4HC40H), 7.95 (t, 2H, C5HC50H), 7.53 (d, 2H, C7HC70H), 7.44
(t, 2H, C6HC60H); for the complex (DMSO-d6, 300 MHz) d ppm:
9.07 (d, 2H, C4HC40H), 8.29 (t, 2H, C5HC50H), 7.84 (d, 2H, C7HC70H),
7.68 (t, 2H, C6HC60H), 7.26 (s, 1H, CHCl3), 3.67 (s, 6H, coord. DMSO);
3JC4HC5H = 8.1; Hz; 3JC5HC6H = 7.8 Hz; 3JC6HC7H = 8.1 Hz. 13C NMR
(DMSO-d6, 75 MHz) d ppm for the ligand: 148.00 (C2), 126.78 (C8,
C9), 125.35(C4,C7), 122.21 (C5,C6); for complex: 155.94 (C2),
153.00 (C20), 131.09 (C8), 127.35 (C80), 127.16 (C9), 127.01(C90),
126.16 (C4), 126.11 (C40), 123.60 (C7), 123.17 (C70), 122.91 (C5,C50),
122.40 (C6,C60), 23.25 (CHCl3), 14.16 (DMSO). ESI(+)-MS: [M]+ C16-
H14N2OS5PtCl: 639.399 a.m.u.; [M]2+ C16H14N2OS5Pt: 302.306.
2.2.2. [Pd2(m-Cl)2(DTBTA)2]Cl2 (2)
The complex 2 was prepared following the general procedure.
Yield 60%. Anal. Calc. for C28H16N4S8Pd2Cl4 (1019.64): C, 32.98; H,
1.58; N, 5.49; S, 25.16; Cl, 13.91; Pd, 20.87%. Found: C, 33.05; H,
1.90; N, 5.75; S, 24.80; Cl, 13.67; Pd, 21.05. Melting point:
>350 C. Conductivity measurements of the complex for 103 M
solution in DMSO afforded a value KM = 34.4 X-1 cm2 mol1 14.
IR (cm1) for the complex 1564 v(C@N), 1156 v(C–N), 1005 v(C–
S), 393 v(Pd–Cl), and 258 v(Pd–N). 1H NMR for the complex
(DMSO-d6, 300 MHz) d ppm: 9.11 (d, 4H, C4HC40H), 9.09 (d, 4H, C7-
HC70H), 7.70 (dd, 4H, C5HC50H), 7.47 (dd, 4H, C6HC60H). 13C NMR
(DMSO-d6, 75 MHz) d ppm for the complex: 132.00 (C4,40), 128.00
(C7,70), 124.00 (C5,50), 126.00 (C6,60). 3JC4HC5H = 8.1 Hz; 3JC5HC6H = 8.1 -
Hz; 3JC6HC7H = 8.1 Hz. ESI(+)-MS: [M]2+C28H16N4S8Pd2Cl2: 473.838
m/z.
2.3. Antimicrobial activity
The antimicrobial activity of the complexes 1 and 2 was deter-
mined using the paper disc plate method as previously
described15,16 using Luria Bertani broth agar medium (LB-agar;
10 g/l Tryptone, 5 g/l yeast extract, 10 g/l NaCl, 18 g/l Bacto agar,
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antimicrobial activities were initially investigated using Kokuria
rhizophila (previously Micrococcus luteus) ATCC934117 and Escheri-
chia coli DH10B as models for Gram-positive and Gram-negative
bacteria, respectively. Thus, antimicrobial activity was also tested
against a collection of pathogenic bacteria, such as toxigenic iso-
lates of Staphylococcus aureus.18 Briefly, a dense suspension of each
microorganism was prepared with a count of approximately 108
cells/ml. A 100 ml of microbial suspension was spread onto LB-agar
plates. Each of the compounds was dissolved in DMSO and solu-
tions of the complexes at different concentrations were prepared
separately. Paper discs of Whatman filter paper (No. 42) of uniform
diameter (6 mm) were cut and sterilized in an autoclave. Different
amounts of complex 1 or complex 2 were directly spotted on ster-
ile paper discs that were placed on the overlay of bacteria on agar
plate in the dark. Growth inhibition halos were observed after
overnight incubation at 37 C. Minimal inhibitory concentration
(MIC) was deduced considering as the lowest concentration of
the compound still able to produce a transparent halo of growth
inhibition larger than 6 mm (size of the disk paper) in a plate con-
taining 20 ml of LB-agar. The antimicrobial activity was calculated
at least as a mean of three replicates. Antimicrobial activities of
complexes 1 and 2 were compared to tetracycline, cisplatin and
the ligand 2,20-dithiobis(benzothiazole) (DTBTA).
2.4. DNA binding activity using gel electrophoresis
For the gel electrophoresis experiments, the method reported
in19 was carried out: different amounts of the complexes were
added to 100 ng of pUC19 DNA in a buffer containing 12.5 mM
Tris-HCl pH = 7.5, 10% glycerol, 62.5 mM KCl, 0.75 mM DTT in a
final volume of 20 ml and incubated for 30 min at room tempera-
ture. 1% agarose gel was prepared in 0.5 TBE buffer (5 TBE:
54 g Tris Base, 27.5 g boric acid, 20 ml of EDTA 0.5 pH = 8). Then
10 ml each of the incubated complex-DNA mixtures (mixed with
bromophenol blue dye at a 1:1 ratio) was loaded on the gel con-
taining EtBr (ethidium bromide) along with the pUC19 DNA as ref-
erence, and the electrophoresis was carried out under 0.5X TBE
buffer system on the dark. At the end of the electrophoresis, the
gel was visualized under UV light using a Bio-Rad Trans illumina-
tor. The illuminated gel was photographed by using a Polaroid
camera.
2.5. Viability assay in vitro
HepG2 and MCF-7 cell lines were grown in RPMI medium sup-
plemented with l-glutamine (2 mM), 10% fetal bovine serum (FBS),
penicillin (100 U/ml), streptomycin (100 lg/ml) and gentamicin
(5 lg/ml). HepG2 culture medium also contained sodium pyruvate
(1.0 mM). Cells were maintained in log phase by seeding twice a
week at a density of 3  108 cells/L in humidified 5% CO2 atmo-
sphere, at 37 C. In all experiments, after plating, cells were
allowed to adhere overnight and then treated with the compounds
or vehicle alone (control cells). No differences were found between
cells treated with DMSO 0.1% and untreated cells in terms of cell
number and viability.
Cytotoxic activity of the complexes 1 and 2 against human
tumor cell lines was determined by the MTT colorimetric assay
based on the reduction of 3-(4,5-dimethyl-2-thiazolyl)bromide-
2,5-diphenyl-2H-tetrazolium (MTT) to purple formazan by mito-
chondrial dehydrogenases of living cells. This method is commonly
used to illustrate inhibition of cellular proliferation. Monolayer
cultures were treated for 24–72 h with various concentrations
(0.1–100 lM) of the drugs. Cisplatin and ligand were used for com-
parison. Briefly, all cell lines were seeded at 2  104 cells/well in
96-well plates containing 200 lL RPMI. When appropriated, cellswere washed with fresh medium and incubated with the com-
pounds in RPMI. After a 24–72 h incubation, cells were washed,
and 50 ll FBS-free medium containing 5 mg/ml MTT were added.
The medium was discarded after 2 h incubation at 37 C by cen-
trifugation, and formazan blue formed in the cells was dissolved
in DMSO. The absorbance, measured at 570 nm in a microplate
reader (Bio-RAD, Hercules, CA), of MTT formazan of control cells
was taken as 100% of viability. IC50 value for each assessed com-
pound was calculated by plotting the percentage viability versus
concentration and reading off the concentration at which 50% of
cells remained viable relative to the control. Each experiment
was repeated at least three times in triplicate to obtain the mean
values.
2.6. Measurement of phosphatidylserine exposure
The externalization of phosphatidylserine (PS) to the cell sur-
face was detected by flow cytometry by double staining with
Annexin V-Fluorescein isothiocyanate (Annexin V-FITC)/propidium
iodide (PI). Phosphatidylserine, which is normally located on the
cytoplasmic surface of cell membranes, is exposed on the cell sur-
face upon induction of apoptosis. Annexin V binds to phos-
phatidylserine and is used to identify the earliest stage of
apoptosis. PI, which does not enter cells with intact membranes,
is used to distinguish between early apoptotic cells (Annexin V-
FITC positive and PI negative) and late apoptotic cells (Annexin
V-FITC/PI-double positive). Tumor cells (HepG2, MCF-7) were
seeded in triplicate in 24-wells culture plates at a density of
5.0  104 cells/cm2. After an overnight incubation, the cells were
washed with fresh medium and incubated with the compounds
in RPMI. After 24 h, cells were harvested by trypsinization and
adjusted at 1.0  106 cells/ml with buffer according to the manu-
facturer’ instructions (eBioscience, San Diego, CA). One hundred
ll of cell suspended solution was added to a new tube, and incu-
bated with Annexin V-FITC and PI solution at room temperature
in the dark for 15 min. Then samples of at least 1.0  104 cells were
subjected to fluorescence-activated cell sorting (FACS) analysis by
Epics XLTM flow cytometer using Expo32 software (Beckman Coul-
ter, Fullerton, CA), using appropriate 2-bidimensional gating
method.
2.7. Cell cycle analysis
Cell cycle stage was analyzed by flow cytometry. Aliquots of
1x106 cells were harvested by centrifugation, washed with PBS
and incubated in the dark in a PBS solution containing 20 lg/ml
propidium iodide (PI) and 200 lg/ml RNase, for 30 min, at room
temperature. Then samples were immediately subjected to FACS
analysis. At least 1  104 cells were analyzed for each sample.
2.8. Acridine orange and Ethidium bromide morphological
fluorescence dye staining
Acridine orange (AO) stains DNA bright green, allowing visual-
ization of the nuclear chromatin pattern and stains both live and
dead cells. Ethidium bromide (EB) stains DNA orange but is
excluded by viable cells. Dual staining allows separate enumera-
tion of populations of viable non apoptotic, viable (early) apoptotic,
nonviable (late) apoptotic, and necrotic cells. Live cells appear uni-
formly green. Early apoptotic cells stain green and contain bright
green dots in the nuclei as a consequence of chromatin condensa-
tion and nuclear fragmentation. Late apoptotic cells incorporate EB
and therefore stain orange, but, in contrast to necrotic cells, the
late apoptotic cells show condensed and often fragmented nuclei.
Necrotic cells stain orange, but have a nuclear morphology resem-
bling that of viable cells, with no condensed chromatin. Briefly,
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1 and 2 for 24 h, the medium was discarded. Cells were washed
with saline 5 mM phosphate buffer (PBS) and then incubated with
100 ll PBS containing 100 lg/ml of EB plus 100 lg/ml of AO. After
20 min, EB/AO solution was discarded and cells immediately visu-
alized by means of fluorescent microscope equipped with an auto-
matic photomicrograph system (Leica, Wetzlar, Germany).
Multiple photos were taken at randomly selected areas of the well
to ensure that the data obtained are representative.2.9. In vitro cellular uptake
For platinum and palladium cellular uptake studies, MCF-7 and
HepG2 cells were incubated with the compounds at 25 lM or
100 lM concentration respectively. After 24 h the cells were
washed three times with cold PBS (Phosphate Buffered Saline), col-
lected by trypsinization and centrifuged at 1000g for 5 min. At the
end the pellet was suspended in Milli-Q water, sonicated and the
platinum and palladium contents measured with Differential Pulse
Voltammetry Amel 433. Instrumental settings were optimized in
order to yield maximum sensitivity for platinum and palladium.
The data were expressed as ng/cell of Pt or Pd, and were the results
of three independent experiments ± SD.Scheme 1. Structure of the ligand and numbering scheme of atoms.
Scheme 2. Procedures of synthesis, structures and nu
Table 1
MIC (mM) of complex 1, complex 2, DTBTA ligand, tetracycline, cisplatin. NA: not active u
Complex 1 Complex 2
K. rhizophila 2.5 7.5
E. coli >20 >203. Results and discussion
3.1. Chemistry
The coordination mode of the complexes was determined by
using the 1H and 13C NMR and IR spectra. NMR spectra were
recorded in DMSO-d6 solution, the assignments of resonances were
based on literature data20 and are in good agreement with the pro-
posed structures (Figs. S1–3). For the ligand, the numbering of pro-
tons used for 1H and 13C NMR is shown in Scheme 1 and the
proposed structures of the complexes are reported in Scheme 2.
The eight proton signals of DTBTA ligand coordinated to Pt(II) ion
for 1 and the sixteen proton signals of two molecules of DTBTA
coordinated to Pd(II) ions for 2 are shifted downfield compared
to the free ligand as reported in literature for similar ligands with
transitional metal ions.20 The protons C4H and C40H in the complex
1 are the most shifted, this confirms that the DTBTA behaves as
bidentate ligand, coordinating Pt(II) ion via N(3) atoms of benzoth-
iazole. The 13C NMR spectrum for the complex 1 shows the same
trend of 1H NMR spectrum in fact the carbons C2, C20, C8, C80, C9
and finally C90, move to lower field compared to the ligand. In the
complex 2 the protons C4H and C7H are more shifted respect to
the ligand and to the complex 1, this fact could be due to the sec-
ond moiety of ligand coordinated to the second Pd(II) ion21,22. The
sharp and high signals in 1H NMR spectra of complexes in DMSO at
24 h and 48 h rule out a ligand substitution and fragmentation by
DMSO. The IR spectrum of the free ligand shows three characteris-
tic bands due to stretching vibration v(C@N), v(C–N) and v(C–S)
respectively for benzotriazole rings. In the IR spectra of complexesmbering scheme of atoms of complexes 1 and 2.
ntil 20 mM.
DTBTA Tetracycline Cisplatin
30 5 5
NA 4 5
Fig. 1. Gel electrophoresis of plasmid DNA in presence of increasing concentrations (0.5–1.5 mg/ml) of complex 1, complex 2 and DTBTA. C indicates the plasmid DNA alone.
The arrows indicate the two forms of the plasmid, the closed circular (Form I) and the nicked one (Form II).
Fig. 2. Effect of the complex 1, complex 2 and relative ligand on the viability of
HepG2 (A) or MCF-7 (B) cells. Cells were treated with the compounds and cell
survival was measured after 24 h by MTT assay in comparison to cells treated with
vehicle alone (control), as reported in Experimental. Cisplatin was used as a positive
control. Values are the mean ± SD of three separate experiments carried out in
triplicate. (C) Table shows IC50 ± SD values relative to the indicated compounds.
Fig. 3. Inhibitory effect of the complex 1 on the growth of HepG2 (A) or MCF-7 (B)
cells. Cell monolayers were incubated for 24–72 h with complex 1 at the indicated
concentrations. Cell viability was assessed by MTT test as reported in Experimental.
Results are indicated as the percentage of viable cells with respect to untreated
controls. Values are the mean ± SD of three separate experiments carried out in
triplicate.
2382 S. Rubino et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2378–23861 and 2, a characteristic band due to v(C@N) vibrations, are shifted
after complexation of the ligand to the metal ions.23 Instead, the
band due to v(C–S) vibration of the ligand is unshifted in both com-
plexes, which confirms the coordination on N(3) of the ligand.
Moreover, the stretching vibrations of Pt–N and Pd–N bonds for
1 and for 2 are very interesting for the coordination of the ligand
to Pt(II) an Pd(II) ions. The presence of v(Pt–Cl) and v(Pd–Cl) bands
in the 1 and in 2 complexes, respectively, were due to stretching
vibrations of Pt–Cl and cis-bridging chloride bonds to Pd(II) ion.24
In the complex 1 a molecule of DMSO is confirmed by two signals
of double S–O and Pt–S bonds.25,26
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3.2.1. Antimicrobial activity
Antimicrobial assays of the complexes 1 and 2 against K. rhi-
zophila and E. coli showed that both are more active against Gram
positive than Gram negative bacteria, complex 1 showed a MIC of
2,5 mM and complex 2 a MIC of 7.5 mM against K. rhizophila, respec-
tively, as shown in Table 1. In our tested conditions, 5 mM of tetra-
cycline and cisplatin were able to inhibit K. rhizophila growth,
respectively, and 2,20-dithiobis(benzothiazole) was active only
against K. rhizophila (MIC of 30 mM). Differently, both complexes
resulted less active in inhibiting the growth of E. coli with MIC lar-
ger than 20 mM. These results demonstrated that complex 1 is
more effective than cisplatin in the inhibition of K. rhizophila; in
both cases complexation with metals improved antibacterial activ-
ity of DTBTA. Moreover, complex 1 resulted more active than cis-
platin against pathogenic Gram-positive bacteria than against
Gram-negative bacteria (data not shown).3.2.2. DNA binding study by gel electrophoresis
As reported in2,6,27, benzothiazole, Pt(II) and Pd(II) complexes
are known to bind DNA. The binding to the DNA of the plasmid
pUC19 was monitored by agarose gel electrophoresis. When elec-
trophoresis is applied to circular plasmid DNA, different forms
could be detected, i.e. a more abundant and faster form due toFig. 4. Flow cytometric analysis for the quantification by AnnexinV/PI double staining of
were incubated for 24 h in the absence (control) or in the presence of the synthesiz
Experimental. Ligand was used as negative control. AH3, viable cells (AnnexinV/PI
(AnnexinV+/PI+); AH1, necrotic cells (AnnexinV/PI+). Representative images of three ethe closed circular conformation (Form I) and a slower-moving
nicked conformation (Form II).
Fig. 1 shows the results of incubation of complex 1, complex 2
and DTBTA with the plasmid pUC19. It has been observed from
gel electrophoresis that the DTBTA has no effect on the plasmid
DNA, while both complexes induced the disappearance of Form I
and II at concentration of 1.5 mg/ml. These results suggest that
both complexes can bind pUC19 DNA. This binding is likely to
occur through intercalation binding mode thanks to the benzothia-
zole ligand.3.2.3. Antitumor activity
Cytotoxicity in vitro of the complex 1 and complex 2 was mea-
sured on two tumor human cell lines, HepG2 (hepatocellular carci-
noma) and MCF-7 (breast cancer), using cisplatin as a positive
control. Monolayer cultures treated for 24 h with 1–100 lM con-
centrations of the compounds were examined by MTT assay for
the cell viability. As shown in Fig. 2 A and B, a clear dose dependent
inhibitory effect of the complex 1 on the viability of both the can-
cer cell lines was measured, whereas complex 2, as well as the
ligand (DTBTA), did not affect the cell viability at any of the consid-
ered concentrations. The calculated half maximal inhibitory con-
centration (IC50) values indicated that cytotoxic efficacy of
complex 1 was two times higher than that exerted by cisplatin
(Fig. 2 C). Moreover, prolonged incubation times (48–72 h) withthe complex 1 induced apoptosis in HepG2 (A) or MCF-7 (B) cells. Cell monolayers
ed complex and submitted to double staining with Annexin V/PI as reported in
); AH4, cells in early apoptosis (AnnexinV+/PI); AH2, cells in tardive apoptosis
xperiments with comparable results.
Fig. 5. Effect of complex 1 on the cell cycle distribution of HepG2 (A) or MCF-7 (B) cells. Flow cytometric analysis of propidium iodide-stained cells after 12 h treatment in the
absence (control) or in the presence of the synthesized complex . Ligand was used as negative control. The percentage of cells in the different phases of the cycle was
calculated by Expo32 software. Representative images of three experiments with comparable results.
2384 S. Rubino et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2378–2386complex 1 resulted in a progressive cell growth inhibition, demon-
strating antiproliferative activity of the compound (Fig. 3). Mecha-
nism of the complex 1 induced cell death (necrosis or apoptosis)
was investigated both on HepG2 and MCF-7 cells by double stain-
ing with propidium iodide (PI) and Annexin V-FITC followed by
cytofluorimetric analysis. The chosen concentrations were selected
on the basis that they represented the IC50 values measured at 24 h
for each cell line. As shown in Fig. 4 the complex 1 induced a clear
shift of viable cells towards early apoptosis in HepG2 or towards
late apoptosis in MCF-7 cells, while did not exert necrotic effects
in any cancer cell line. Cells treated with DTBTA at 100 lM, as a
negative control, showed a dot plot quite similar to the control
cells. Moreover, to determine alterations in the cell cycle caused
by the complex 1, flow cytometry analysis of nuclear DNA content
after 12 h treatment of HepG2 and MCF7 cells was carried out.
Compared to control cells, complex 1 caused, in both the cancer
cell lines, an accumulation of cells in G0/G1phase, paralleled by a
reduction in the percentage of cells in the S and G2/M phases
(Fig. 5).
To confirm apoptotic mechanism of cytotoxicity of the studied
complex 1, we carried out morphological evaluation of the HepG2
and MCF-7 tumor cells using AO and EB fluorescent DNA binding
dyes. The fluorescent microscopy revealed that the nucleus of the
control cells was round and the cells stained green, indicating theywere normal (Fig. 6). Treatment with 1 for 24 h at IC50 concentra-
tion caused changes to cell morphology of both tumor lines, with
the appearance of cells containing bright green patches in the
nuclei as a consequence of chromatin condensation and nuclear
fragmentation, which are typical features of apoptosis (Fig. 6).
Moreover, fluorescing orange cells owing to increase of cell perme-
ability to ethidium bromide, cell shrinkage and membrane blub-
bing were also evident as cells in late apoptosis, chiefly in MCF-7
cell line (Fig. 6 B). In order to better understand the cytotoxic activ-
ity of the new complexes of platinum and palladium, we have
determined cellular platinum uptake on MCF-7 and HepG2 cells
after 24 h continuous exposure with 25 mM or 100 mM concentra-
tion compounds. The amount of intracellular platinum, evaluated
for complex 1 gave a value of 9.5  104 ng/cell on MCF-7 and
8.2  104 ng/cell on HepG2 cells respectively and the absence of
intracellular palladium for complex 2.4. Conclusion
Two new mono-Pt(II) and binuclear chloro-bridged Pd(II) com-
plexes with DTBTA ligand were synthesized and characterized. Dif-
ferent structures for 1 and 2 complexes were found; in the complex
1, the coordination of Pt(II) ion involves the N(3) atoms of the
Fig. 6. Fluorescence micrographs of EB/AO double stained HepG2 (A), MCF-7 (B) cells after treatment with complex 1. Cells were incubated for 24 h in the absence (control) or
in the presence of the synthesized complex and submitted to double staining with AO/EB as reported in Experimental. Ligand was used as negative control. Arrows indicate
membrane blubbing. Representative images of three experiments with comparable results (200 magnifications).
S. Rubino et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2378–2386 2385ligand that acts in a bidentate mode. In binuclear complex 2, two
Pd(II) ions are linked to two molecules of the ligand through
chloro-bridged atoms. The geometry of the complexes is square
planar, but the structures of 1 and 2 are very different, the second
compound is a steric hindered complex. The different structures
reflect a different behavior in the antimicrobial and in the antitu-
mor activity. In fact, only 1 shows a dose-dependent anti-prolifer-
ative effect against the two tumor cell lines associated to cell
apoptosis, while both 1 and 2 exhibit antimicrobial activity with
complex 1more active against Gram positive bacterial growth than
cisplatin. The low activity against Gram negative bacteria could be
due to the presence of an additional outer membrane in this group
of bacteria that could hinder the uptake of both compounds.
Complex 1 is effective inducer of apoptotic death on HepG2 and
MCF-7 cells and causes cell arrest at G0/G1 phase. Apoptosis effect
is associated with externalization of plasma membrane phos-
phatidylserine, chromatin condensation, nuclear fragmentation
and membrane blubbing. Complex 2 is ineffective, indicating that
only the coordination with Pt(II) ion confers to DTBTA potential
pharmacological properties. Both complexes were found to bind
DNA, and we can surmise that the binding is due to intercalation
binding mode thanks to the benzothiazole ligand. The different
behavior of the two complexes depends upon the different uptake,
indeed uptake study demonstrated only the presence of intracellu-lar platinum in HepG2 and MCF-7 cells, suggesting that the Pd(II)
complex cannot enter into the cells likely for its dimeric structure.
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